A Multi-Centre, Prospective, Non-Interventional Study to Intensively Monitor the Safety of Osimertinib in Clinical Practice among Chinese NSCLC Patients

Study identifier:D5160R00026

ClinicalTrials.gov identifier:NCT03485326

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Multi-Centre, Prospective, Non-Interventional Study to Intensively Monitor the Safety of Osimertinib in Clinical Practice among Chinese NSCLC Patients An observational study conducted among Chinese NSCLC patients to evaluate Osimertinib safety profile in a real world setting

Medical condition

Non-small Cell Lung Cancer

Phase

Phase 4

Healthy volunteers

No

Study drug

-

Sex

All

Actual Enrollment

1700

Study type

Observational

Age

n/a - n/a

Date

Study Start Date: 21 Apr 2020
Primary Completion Date: 03 Aug 2023
Study Completion Date: 03 Aug 2023

Study design

Allocation: Non-randomized
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Jul 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria